Learn about who we are,
what we do, and why it matters.
Because it is exceptionally sensitive and accurate, immunosequencing propels us from identifying thousands, to revealing millions of unique T or B cells in a single biologic sample.
Adaptive’s immunosequencing platform provides researchers, collaborators and industry partners with the highest resolution view into a patient’s dynamic adaptive immune system.
Preliminary data indicates that the number of TILs and the diversity of the TIL population positively correlate to outcomes, including overall survival.
AACR 2016: Vice President Biden’s National Cancer Moonshot Initiative Calls for Better Tools, Better Sharing
We are on the cusp of a real inflection point in the fight against cancer. We need to share this data in order to move the process more rapidly.” - Vice President Joseph Biden AACR 2016 Speech
These data strongly emphasize the importance of understanding and monitoring T-cell response in patients receiving immunotherapies.
Scientists and doctors need molecular information to understand mechanisms of action, develop prognostic indicators, and construct the most effective treatment strategies.
Assessment of the repertoire using the immunoSEQ Assay could give physicians an additional window of time to modify treatment...
The FDA and numerous pharmaceutical and biotech companies have set their sights on minimal residual disease (MRD) evaluation as a new method for measuring deeper response rates.
With the advances across blood cancers, it is once again time to look to MRD testing to help push responses farther.
A rapid convergence of immunotherapy, personalized medicine and new theranostics is taking place.
There is an urgent need for a new class of immune molecular diagnostics to better stratify and predict a patient’s response…
The results are specific for each patient, but the assay itself is universal and standardized.
The single biggest step forward in understanding the complexities of the immune system that's occurred in the last 5-10 years. — Edus Warren, M.D., Ph. D., Fred Hutchinson Cancer Research Center
There’s every reason to believe that myeloma, as a disease, is on the ropes.
Improved survival rates are a product of increased rates of response to treatment and increased depth of these responses.
One of the less-appreciated features is its ability to track multiple cancer clones, which has implications for both patient care and our understanding of disease biology.
No matter how many advancements we make, there’s always more to learn and more to do.
Load More +